Jonathan L Bramson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8557574/publications.pdf Version: 2024-02-01

		66234	95083
129	5,782	42	68
papers	citations	h-index	g-index
133	133	133	7409
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Metformin-induced reductions in tumor growth involves modulation of the gut microbiome. Molecular Metabolism, 2022, 61, 101498.	3.0	21
2	The histologic effects of neoadjuvant stereotactic body radiation therapy (SBRT) followed by pulmonary metastasectomy—rationale and protocol design for the Post SBRT Pulmonary Metastasectomy (PSPM) trial. Translational Cancer Research, 2022, 11, 918-927.	0.4	2
3	Peanut allergen reaction thresholds during controlled food challenges in 2 Canadian randomized studies (Canada-ARM1 and PISCES). Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2524-2526.e2.	2.0	2
4	Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. IScience, 2021, 24, 102619.	1.9	33
5	Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma. Cytotherapy, 2021, 23, 820-832.	0.3	5
6	Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections. Viruses, 2021, 13, 2239.	1.5	10
7	Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency. Oncolmmunology, 2021, 10, 1995168.	2.1	2
8	De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors. Communications Biology, 2020, 3, 645.	2.0	30
9	A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity. Molecular Therapy - Oncolytics, 2020, 17, 278-292.	2.0	9
10	The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell, 2020, 26, 832-844.e6.	5.2	114
11	A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy. Cytokine and Growth Factor Reviews, 2020, 56, 149-159.	3.2	3
12	Tonic Signaling Leads to Off-Target Activation of T Cells Engineered with Chimeric Antigen Receptors That Is Not Seen in T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors. Blood, 2020, 136, 31-32.	0.6	1
13	TGFβ Programs Central Memory Differentiation in <i>Ex Vivo</i> –Stimulated Human T Cells. Cancer Immunology Research, 2019, 7, 1426-1439.	1.6	19
14	Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncolmmunology, 2019, 8, e1512329.	2.1	53
15	Endogenous T cells prevent tumor immune escape following adoptive T cell therapy. Journal of Clinical Investigation, 2019, 129, 5400-5410.	3.9	76
16	The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. Nature Communications, 2018, 9, 3049.	5.8	82
17	Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. Cancer Immunology Research, 2018, 6, 1174-1185.	1.6	38
18	HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants. Cell Reports, 2018, 24, 642-654.	2.9	19

#	Article	IF	CITATIONS
19	Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity. Journal of Clinical Investigation, 2018, 129, 518-530.	3.9	32
20	T Cells Engineered with a Novel Chimeric Receptor Demonstrate Durable In Vivo Efficacy Against Disseminated Multiple Myeloma. Blood, 2018, 132, 962-962.	0.6	3
21	T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors for Haematological Malignancies. Blood, 2018, 132, 3267-3267.	0.6	1
22	<scp>AMPK</scp> β1 reduces tumor progression and improves survival in p53 null mice. Molecular Oncology, 2017, 11, 1143-1155.	2.1	28
23	Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells. Cell Death and Disease, 2017, 8, e2689-e2689.	2.7	24
24	Tumor-targeting domains for chimeric antigen receptor T cells. Immunotherapy, 2017, 9, 33-46.	1.0	7
25	Serum C-Reactive Protein and Congestive Heart Failure as Significant Predictors of Herpes Zoster Vaccine Response in Elderly Nursing Home Residents. Journal of Infectious Diseases, 2017, 216, 191-197.	1.9	29
26	T ell Phenotypes Predictive of Frailty and Mortality in Elderly Nursing Home Residents. Journal of the American Geriatrics Society, 2017, 65, 153-159.	1.3	46
27	Adaptive Resistance to Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2017, 1036, 213-227.	0.8	15
28	Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence. PLoS ONE, 2016, 11, e0155947.	1.1	68
29	Estradiol Enhances CD4+ T-Cell Anti-Viral Immunity by Priming Vaginal DCs to Induce Th17 Responses via an IL-1-Dependent Pathway. PLoS Pathogens, 2016, 12, e1005589.	2.1	55
30	Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination. Journal of Immunology, 2016, 196, 4587-4595.	0.4	35
31	Induction of an Immune-Protective T-Cell Repertoire With Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans. Journal of Infectious Diseases, 2016, 214, 1996-2005.	1.9	25
32	Characterization of Proliferating Lesionâ€Resident Cells During All Stages of Atherosclerotic Growth. Journal of the American Heart Association, 2016, 5, .	1.6	28
33	Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes. Methods in Molecular Biology, 2016, 1458, 137-157.	0.4	8
34	Immunogenicity of Varicella Vaccine and Immunologic Predictors of Response in a Cohort of Elderly Nursing Home Residents. Journal of Infectious Diseases, 2016, 214, 1905-1910.	1.9	33
35	Immediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells. Journal of Immunology, 2016, 197, 1809-1822.	0.4	41
36	Chimeric antigen receptor–engineered T cells as oncolytic virus carriers. Molecular Therapy - Oncolytics, 2015, 2, 15014.	2.0	53

#	Article	IF	CITATIONS
37	An Introduction to Automated Flow Cytometry Gating Tools and Their Implementation. Frontiers in Immunology, 2015, 6, 380.	2.2	83
38	Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. , 2015, 3, 55.		60
39	Circulating TNF and mitochondrial DNA are major determinants of neutrophil phenotype in the advanced-age, frail elderly. Molecular Immunology, 2015, 65, 148-156.	1.0	45
40	Circulating Muramyl Dipeptide Is Negatively Associated with Interleukin-10 in the Frail Elderly. Inflammation, 2015, 38, 272-277.	1.7	13
41	T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice. Molecular Therapy, 2015, 23, 1600-1610.	3.7	58
42	Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity. Innate Immunity, 2015, 21, 626-634.	1.1	12
43	Alterations to the Frequency and Function of Peripheral Blood Monocytes and Associations with Chronic Disease in the Advanced-Age, Frail Elderly. PLoS ONE, 2014, 9, e104522.	1.1	77
44	Maraba Virus as a Potent Oncolytic Vaccine Vector. Molecular Therapy, 2014, 22, 420-429.	3.7	134
45	Immunotherapy-induced CD8+ T Cells Instigate Immune Suppression in the Tumor. Molecular Therapy, 2014, 22, 206-218.	3.7	65
46	Anti-pneumococcal deficits of monocyte-derived macrophages from the advanced-age, frail elderly and related impairments in PI3K-AKT signaling. Human Immunology, 2014, 75, 1192-1196.	1.2	34
47	Analysis of purified Wild type and mutant adenovirus particles by SILAC based quantitative proteomics. Journal of General Virology, 2014, 95, 2504-2511.	1.3	13
48	Immunosenescence in the nursing home elderly. BMC Geriatrics, 2014, 14, 50.	1.1	22
49	Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop. BMC Infectious Diseases, 2014, 14, 246.	1.3	32
50	Immune Biomarkers Predictive of Respiratory Viral Infection in Elderly Nursing Home Residents. PLoS ONE, 2014, 9, e108481.	1.1	43
51	Blood CD33(+)HLA-DR(â^') myeloid-derived suppressor cells are increased with age and a history of cancer. Journal of Leukocyte Biology, 2013, 93, 633-637.	1.5	199
52	HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy. Molecular Therapy, 2013, 21, 887-894.	3.7	98
53	A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity. Science Translational Medicine, 2013, 5, 205ra134.	5.8	184
54	Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8 ⁺ T-cell responses to anticancer vaccines. Oncolmmunology, 2013, 2, e26013.	2.1	51

#	Article	IF	CITATIONS
55	Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8+ T-cell recall responses. Blood, 2013, 121, 2432-2439.	0.6	36
56	The Polyfunctionality of Human Memory CD8+ T Cells Elicited by Acute and Chronic Virus Infections Is Not Influenced by Age. PLoS Pathogens, 2012, 8, e1003076.	2.1	72
57	Combined mTOR Inhibition and OX40 Agonism Enhances CD8+ T Cell Memory and Protective Immunity Produced by Recombinant Adenovirus Vaccines. Molecular Therapy, 2012, 20, 860-869.	3.7	9
58	Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncolmmunology, 2012, 1, 419-431.	2.1	25
59	IL-15 Can Signal via IL-15Rî±, JNK, and NF-κB To Drive RANTES Production by Myeloid Cells. Journal of Immunology, 2012, 188, 4149-4157.	0.4	40
60	Association between HLA Class I and Class II Alleles and the Outcome of West Nile Virus Infection: An Exploratory Study. PLoS ONE, 2011, 6, e22948.	1.1	33
61	CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells. Blood, 2011, 117, 1146-1155.	0.6	42
62	Novel method for differentiation between Trastuzumab and host adaptive response. Molecular Immunology, 2011, 48, 1882-1885.	1.0	0
63	Optimizing vaccine-induced CD8+T-cell immunity: focus on recombinant adenovirus vectors. Expert Review of Vaccines, 2011, 10, 1307-1319.	2.0	31
64	Adenoviral-transduced dendritic cells are susceptible to suppression by T regulatory cells and promote interleukin 17 production. Cancer Immunology, Immunotherapy, 2011, 60, 381-388.	2.0	3
65	Interactions Between the Immune System and Cancer: AÂBrief Review ofÂNon-spatial Mathematical Models. Bulletin of Mathematical Biology, 2011, 73, 2-32.	0.9	330
66	Multi-Stability and Multi-Instability Phenomena in a Mathematical Model of Tumor-Immune-Virus Interactions. Bulletin of Mathematical Biology, 2011, 73, 2932-2961.	0.9	45
67	IL-15 and Type I Interferon Are Required for Activation of Tumoricidal NK Cells by Virus-Infected Dendritic Cells. Cancer Research, 2011, 71, 2497-2506.	0.4	49
68	IL-1α/IL-1R1 Expression in Chronic Obstructive Pulmonary Disease and Mechanistic Relevance to Smoke-Induced Neutrophilia in Mice. PLoS ONE, 2011, 6, e28457.	1.1	128
69	Combining Cancer Vaccines with Conventional Therapies. , 2011, , 323-338.		0
70	Modeling anti-tumor Th1 and Th2 immunity in the rejection of melanoma. Journal of Theoretical Biology, 2010, 265, 467-480.	0.8	39
71	Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes – relevance for vaccine design. Immunome Research, 2010, 6, S6.	0.1	14
72	Identification of CD8+ T Cell Epitopes in the West Nile Virus Polyprotein by Reverse-Immunology Using NetCTL. PLoS ONE, 2010, 5, e12697.	1.1	41

#	Article	IF	CITATIONS
73	Surface Phenotype and Functionality of WNV Specific T Cells Differ with Age and Disease Severity. PLoS ONE, 2010, 5, e15343.	1.1	16
74	Mesenchymal Stromal Cells Expressing ErbB-2/ <i>neu</i> Elicit Protective Antibreast Tumor Immunity <i>In vivo</i> , Which Is Paradoxically Suppressed by IFN-γ and Tumor Necrosis Factor-α Priming. Cancer Research, 2010, 70, 7742-7747.	0.4	18
75	Immunotherapy Can Reject Intracranial Tumor Cells without Damaging the Brain despite Sharing the Target Antigen. Journal of Immunology, 2010, 184, 4269-4275.	0.4	16
76	Processing of Tumor Antigen Differentially Impacts the Development of Helper and Effector CD4+ T-cell Responses. Molecular Therapy, 2010, 18, 1224-1232.	3.7	5
77	Potentiating Cancer Immunotherapy Using an Oncolytic Virus. Molecular Therapy, 2010, 18, 1430-1439.	3.7	146
78	Persistence of Transgene Expression Influences CD8 ⁺ T-Cell Expansion and Maintenance following Immunization with Recombinant Adenovirus. Journal of Virology, 2009, 83, 12027-12036.	1.5	52
79	Neoadjuvant Vaccination Provides Superior Protection against Tumor Relapse following Surgery Compared with Adjuvant Vaccination. Cancer Research, 2009, 69, 3979-3985.	0.4	25
80	Recombinant Vesicular Stomatitis Virus Transduction of Dendritic Cells Enhances Their Ability to Prime Innate and Adaptive Antitumor Immunity. Molecular Therapy, 2009, 17, 1465-1472.	3.7	66
81	Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With Adenovirus. Molecular Therapy, 2009, 17, 1814-1821.	3.7	95
82	CD4 ⁺ Tâ€cellâ€mediated antiâ€tumor immunity can be uncoupled from autoimmunity <i>via</i> the STAT4/STAT6 signaling axis. European Journal of Immunology, 2009, 39, 1252-1259.	1.6	25
83	Deciphering epitope specificities within polyserum using affinity selection of random peptides and a novel algorithm based on pattern recognition theory. Molecular Immunology, 2009, 46, 429-436.	1.0	8
84	A novel computer algorithm improves antibody epitope prediction using affinity-selected mimotopes: A case study using monoclonal antibodies against the West Nile virus E protein. Molecular Immunology, 2008, 46, 125-134.	1.0	22
85	The Memory T Cell Response to West Nile Virus in Symptomatic Humans following Natural Infection Is Not Influenced by Age and Is Dominated by a Restricted Set of CD8+T Cell Epitopes. Journal of Immunology, 2008, 181, 1563-1572.	0.4	27
86	Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2981-2986.	3.3	59
87	Enhanced Antitumor Immunity Elicited by Dendritic Cell Vaccines Is a Result of Their Ability to Engage Both CTL and IFNÎ ³ -producing NK Cells. Molecular Therapy, 2008, 16, 411-418.	3.7	57
88	Tumor Protection Following Vaccination With Low Doses of Lentivirally Transduced DCs Expressing the Self-antigen erbB2. Molecular Therapy, 2008, 16, 607-617.	3.7	26
89	Antigen Presentation by Exosomes Released from Peptide-Pulsed Dendritic Cells Is not Suppressed by the Presence of Active CTL. Journal of Immunology, 2007, 179, 5024-5032.	0.4	117
90	T-cell immunity generated by recombinant adenovirus vaccines. Expert Review of Vaccines, 2007, 6, 347-356.	2.0	29

#	Article	IF	CITATIONS
91	Elevated Frequencies of Self-reactive CD8+ T Cells following Immunization with a Xenoantigen Are Due to the Presence of a Heteroclitic CD4+ T-Cell Helper Epitope. Cancer Research, 2007, 67, 6459-6467.	0.4	32
92	On the Role of CD4+ T Cells in the CD8+ T-Cell Response Elicited by Recombinant Adenovirus Vaccines. Molecular Therapy, 2007, 15, 997-1006.	3.7	34
93	Induction of Epitope-Specific Neutralizing Antibodies against West Nile Virus. Journal of Virology, 2007, 81, 11828-11839.	1.5	157
94	Critical Negative Regulation of Type 1 T Cell Immunity and Immunopathology by Signaling Adaptor DAP12 during Intracellular Infection. Journal of Immunology, 2007, 179, 4015-4026.	0.4	35
95	Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine, 2007, 25, 1342-1352.	1.7	69
96	11-OR: Interaction of HLA-a*0201 and west nile virus. Human Immunology, 2007, 68, S14.	1.2	0
97	The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector. Cellular Immunology, 2007, 250, 55-67.	1.4	15
98	Inhalation Tolerance Is Induced Selectively in Thoracic Lymph Nodes but Executed Pervasively at Distant Mucosal and Nonmucosal Tissues. Journal of Immunology, 2006, 176, 2568-2580.	0.4	17
99	The CD8+ T Cell Population Elicited by Recombinant Adenovirus Displays a Novel Partially Exhausted Phenotype Associated with Prolonged Antigen Presentation That Nonetheless Provides Long-Term Immunity. Journal of Immunology, 2006, 176, 200-210.	0.4	77
100	Development of Cell-Based Tuberculosis Vaccines: Genetically Modified Dendritic Cell Vaccine Is a Much More Potent Activator of CD4 and CD8 T Cells Than Peptide- or Protein-Loaded Counterparts. Molecular Therapy, 2006, 13, 766-775.	3.7	26
101	Recombinant Adenovirus Vaccines Can Successfully Elicit CD8+ T Cell Immunity under Conditions of Extreme Leukopenia. Molecular Therapy, 2006, 13, 270-279.	3.7	9
102	Recent Advances in the Development of Adenovirus- and Poxvirus- Vectored Tuberculosis Vaccines. Current Gene Therapy, 2005, 5, 485-492.	0.9	39
103	Cutaneous Antigen Priming via Gene Gun Leads to Skin-Selective Th2 Immune-Inflammatory Responses. Journal of Immunology, 2005, 174, 1664-1674.	0.4	34
104	Semliki Forest virus and Kunjin virus RNA replicons elicit comparable cellular immunity but distinct humoral immunity. Vaccine, 2005, 23, 4189-4194.	1.7	10
105	Helper-Dependent Adenoviral Vectors Containing Modified Fiber for Improved Transduction of Developing and Mature Muscle Cells. Human Gene Therapy, 2004, 15, 179-188.	1.4	23
106	Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin. Cancer Research, 2004, 64, 1509-1514.	0.4	80
107	CTL-Dependent and -Independent Antitumor Immunity Is Determined by the Tumor Not the Vaccine. Journal of Immunology, 2004, 172, 5200-5205.	0.4	29
108	A Switch in Costimulation from CD28 to 4-1BB during Primary versus Secondary CD8 T Cell Response to Influenza In Vivo. Journal of Immunology, 2004, 172, 981-988.	0.4	117

#	Article	IF	CITATIONS
109	The efficacy of electroporated plasmid vaccines correlates with long-term antigen production in vivo. Vaccine, 2004, 22, 2517-2523.	1.7	22
110	Protection from endotoxemia by adenoviral-mediated gene transfer of human bactericidal/permeability-increasing protein. Blood, 2004, 103, 93-99.	0.6	25
111	TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. Journal of Clinical Investigation, 2004, 113, 401-413.	3.9	166
112	Super-activated interferon-regulatory factors can enhance plasmid immunization. Vaccine, 2003, 21, 1363-1370.	1.7	28
113	DetailedAnalysis of the CD8 + T-Cell Response followingAdenovirusVaccination. Journal of Virology, 2003, 77, 13407-13411.	1.5	67
114	Electroporation Enables Plasmid Vaccines to Elicit CD8+ T Cell Responses in the Absence of CD4+ T Cells. Journal of Immunology, 2003, 171, 3379-3384.	0.4	33
115	Adenoviral Vectors for Gene Delivery. Drugs and the Pharmaceutical Sciences, 2003, , .	0.1	0
116	The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen. Expert Opinion on Biological Therapy, 2002, 2, 75-85.	1.4	22
117	In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. Cancer Research, 2002, 62, 5148-52.	0.4	40
118	Role of Dendritic Cell-Derived Cytokines in Immune Regulation. Current Pharmaceutical Design, 2001, 7, 977-992.	0.9	30
119	Dendritic Cell-Derived IL-12 Is Not Required for the Generation of Cytotoxic, IFN-Î ³ -Secreting, CD8+CTL In Vivo. Journal of Immunology, 2001, 167, 5027-5033.	0.4	36
120	Activation of host antitumoral responses by cationic lipid/DNA complexes. Cancer Gene Therapy, 2000, 7, 353-359.	2.2	26
121	Adenoviral vectors: prospects for gene delivery to the central nervous system. Gene Therapy, 1999, 6, 1349-1350.	2.3	9
122	Effects of Stuffer DNA on Transgene Expression from Helper-Dependent Adenovirus Vectors. Journal of Virology, 1999, 73, 8027-8034.	1.5	90
123	Dendritic Cells Transduced with an Adenoviral Vector Encoding a Model Tumor-Associated Antigen for Tumor Vaccination. Human Gene Therapy, 1997, 8, 1355-1363.	1.4	139
124	ANTI-INTERLEUKIN-12 THERAPY PROTECTS MICE IN LETHAL ENDOTOXEMIA BUT IMPAIRS BACTERIAL CLEARANCE IN MURINE ESCHERICHIA COLI PERITONEAL SEPSIS. Shock, 1997, 8, 349-356.	1.0	70
125	The use of adenoviral vectors for gene therapy and gene transfer in vivo. Current Opinion in Biotechnology, 1995, 6, 590-595.	3.3	106
126	Potentiation of chlorambucil toxicity in B-CLL lymphocytes using the DNA synthesis inhibitors aphidicolin and 1-Î2-d-arabinofuranosylcytosine. Biochemical Pharmacology, 1995, 50, 131-135.	2.0	3

#	Article	IF	CITATIONS
127	Effect of alkyl-N-purine DNA glycosylase overexpression on cellular resistance to bifunctional alkylating agents. Biochemical Pharmacology, 1995, 50, 39-44.	2.0	18
128	DNA repair enzyme expression in chronic lymphocytic leukemia vis-Ã-vis nitrogen mustard drug resistance. Cancer Letters, 1995, 90, 139-148.	3.2	25
129	Lack of evidence for a high-affinity sarcosinamide carrier or a catecholamine carrier in Calu-1 lung-cancer cells, HT-29 colon-cancer cells, and DHF fibroblasts. Cancer Chemotherapy and Pharmacology, 1992, 31, 146-150.	1.1	0